FERRAU', Francesco
 Distribuzione geografica
Continente #
EU - Europa 5.757
NA - Nord America 4.292
AS - Asia 3.061
SA - Sud America 969
AF - Africa 87
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 14.172
Nazione #
US - Stati Uniti d'America 4.190
RU - Federazione Russa 3.341
SG - Singapore 1.273
CN - Cina 905
BR - Brasile 828
IE - Irlanda 582
SE - Svezia 494
IT - Italia 368
HK - Hong Kong 318
DE - Germania 211
VN - Vietnam 204
PL - Polonia 174
FR - Francia 171
GB - Regno Unito 161
IN - India 87
FI - Finlandia 80
AR - Argentina 45
MX - Messico 42
CA - Canada 41
UA - Ucraina 39
TR - Turchia 36
BD - Bangladesh 33
ZA - Sudafrica 30
BE - Belgio 27
ID - Indonesia 25
EC - Ecuador 22
IQ - Iraq 22
UZ - Uzbekistan 21
CO - Colombia 20
JP - Giappone 20
PK - Pakistan 19
AT - Austria 18
MA - Marocco 18
NL - Olanda 17
VE - Venezuela 16
ES - Italia 14
CZ - Repubblica Ceca 12
PE - Perù 11
SA - Arabia Saudita 11
CL - Cile 10
KE - Kenya 10
LT - Lituania 10
AE - Emirati Arabi Uniti 9
PH - Filippine 9
JO - Giordania 8
KG - Kirghizistan 8
MY - Malesia 7
TN - Tunisia 7
AL - Albania 6
IL - Israele 6
PY - Paraguay 6
CI - Costa d'Avorio 5
NP - Nepal 5
OM - Oman 5
PA - Panama 5
UY - Uruguay 5
AZ - Azerbaigian 4
BO - Bolivia 4
DZ - Algeria 4
SN - Senegal 4
SY - Repubblica araba siriana 4
BY - Bielorussia 3
CH - Svizzera 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GE - Georgia 3
HR - Croazia 3
LV - Lettonia 3
MD - Moldavia 3
NG - Nigeria 3
AM - Armenia 2
AU - Australia 2
CG - Congo 2
DK - Danimarca 2
ET - Etiopia 2
GR - Grecia 2
GT - Guatemala 2
JM - Giamaica 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
NI - Nicaragua 2
NO - Norvegia 2
PT - Portogallo 2
SR - Suriname 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
EG - Egitto 1
HU - Ungheria 1
IR - Iran 1
KH - Cambogia 1
KR - Corea 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 14.163
Città #
Moscow 923
Ashburn 738
Singapore 674
Dublin 581
Chandler 482
Dallas 465
Beijing 334
Hong Kong 315
Nyköping 300
San Jose 237
The Dalles 171
Warsaw 163
Messina 153
Los Angeles 126
Jacksonville 123
Munich 109
Princeton 101
Medford 93
Lauterbourg 92
New York 79
Ann Arbor 74
Dearborn 73
Des Moines 70
Cambridge 64
São Paulo 61
Ho Chi Minh City 56
Lancaster 54
Shenyang 40
Hanoi 39
Redondo Beach 38
Buffalo 36
Jinan 34
Orem 34
Tianjin 34
Brooklyn 32
Frankfurt am Main 31
Council Bluffs 30
Guangzhou 29
Boardman 28
Brussels 26
Hyderabad 26
Wilmington 26
London 25
Rio de Janeiro 25
Seattle 25
Helsinki 24
Turku 24
Belo Horizonte 23
Houston 23
Nanjing 22
Santa Clara 22
Catania 21
Curitiba 20
Tashkent 20
Tokyo 19
Johannesburg 17
Montreal 17
San Mateo 17
Atlanta 16
Denver 15
Jakarta 15
Vienna 15
Chennai 14
Dong Ket 14
Milan 14
Pune 14
Stockholm 14
Zhengzhou 14
Brasília 13
Ankara 12
Bremen 12
Düsseldorf 12
Hangzhou 12
Nanchang 12
Poplar 12
Shenzhen 12
Campinas 11
Manchester 11
Nuremberg 11
Porto Alegre 11
Chicago 10
Haikou 10
Hillsboro 10
Mexico City 10
Ningbo 10
Taizhou 10
Toronto 10
Woodbridge 10
Baghdad 9
Boston 9
Da Nang 9
Goiânia 9
Nairobi 9
Ribeirão Preto 9
Rome 9
San Francisco 9
Shanghai 9
Amsterdam 8
Bishkek 8
Biên Hòa 8
Totale 8.009
Nome #
Aggressive pituitary adenomas: the dark side of the moon 251
Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas 245
Aggiornamento sulla chirurgia ipofisaria per via endoscopica: indicazioni, vantaggi e limiti 225
Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. 204
Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide 204
Cyberknife stereotactic treatment of pituitary adenomas: A single center experience using different irradiation schemes and modalities 198
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 191
Diabetes secondary to acromegaly: Physiopathology, clinical features and effects of treatment 189
Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies 187
Course of Pregnancy in Cushing Disease under Different Management Approaches (No Treatment, Surgery, Gamma-Knife or Ketoconazole) 179
Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden 179
Peptide receptor radionuclide therapy with 111IN-DTPA-Octreotide in a woman with Cabergoline-resistant giant prolactinoma 178
An extremely rare association of TSH-secreting pituitary adenoma, metastatic neuroendocrine tumor and Cushing’s syndrome in a patient with MEN-1 gene mutation 177
P-57 Increased prevalence of acromegaly in an industrialized area of north-east of Sicily: a case-control study 176
Global epidemiology of acromegaly: A systematic review and meta-analysis 176
Effectiveness and safety of long-term pegvisomant administration in patients with acromegaly not controlled by other therapies: experience of an Italian center. 174
Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study 174
Increased prevalence of acromegaly in a highly polluted area. 172
High bone marrow fat in patients with Cushing’s syndrome and vertebral fractures 172
Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study 171
Comment to ‘glucocorticoid resistance syndrome caused by a novel nr3c1 point mutation’ by al argan et al. 169
PRIMARY EMPTY SELLA IS ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK, REGARDLESS THE OCCURRENCE OF PITUITARY DYSFUNCTION 168
Effects of cyberknife radiotherapy treatment of pituitary adenomas 168
Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas. 167
Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL. 164
GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly 164
Course of pregnancies in women with Cushing's disease treated by gamma-knife 160
Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas 159
Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly 159
Epidemiologia degli adenomi ipofisari nel nord-est della Sicilia 154
Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide 152
Adrenal Cushing Syndrome: Diagnosis and Management in a 10-Year-Old Boy with Carney Complex 150
Multidisciplinary management of pituitary apoplexy 150
Resistance to somatostatin analogues is associated with GSTP1 gene methylation and AHR rs2066853 variant in acromegaly patients 150
Biochemical control and clinical improvement is induced by long-term pasireotide administration in the majority of patients with Cushing[apos]s disease persistent after pituitary surgery 149
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 147
MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior 144
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective 144
Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing's disease. 143
Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing's disease: an Italian, multicenter study 143
Increased interleukin 22 circulating levels in patients with tumors involving the hypothalamic-pituitary region 142
Thyroid nodules in growth hormone replaced patients. 140
First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy 140
Establishment of a protocol to extend the lifespan of human hormone-secreting pituitary adenoma cells 140
An unusual case of idiopathic hyperprolactinemia 137
A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score 135
Temozolomide-induced shrinkage of a pituitary carcinoma. 134
Environmental Endocrinology and Endocrine Disruptors: Environmental Impact on the Hypothalamus–Pituitary Axis 133
Absence of GNAS1 mutations in somatotropinomas from AIPmut positive patients: possible implications for phenotype. 133
Increased serum brain natriuretic peptide levels are a major predictor of myocardial hypertrophy in acromegalic patients. 133
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 133
Effects Of Epigenetic Changes In Gstp1 And Mgmt Gene On Clinicopathological Fatures Of Acromegaly Patients 133
Genetic and epigenetic modulation of AHR pathway in GH-secreting pituitary tumors and effects on acromegaly clinical phenotype 128
Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing’s disease: a monocentric experience in Southern Italy 127
Health-related quality of life in patients with Cushing's syndrome 127
Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma 121
Endocrinologia & Malattie del Metabolismo 120
The man with acromegaly who inspired the Shrek animated project. 119
First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. 118
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 117
Oral mucositis induced by treatment with soft gel formulation of levothyroxine 117
Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence 116
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis 115
Pitfalls in the 2017 TNM Classification of Thyroid Carcinoma 115
Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma 113
Trabecular bone score, bone marrow fat and vertebral fractures in cushing syndrome 106
Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegaly 106
Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors 103
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas 102
Are comorbidities of patients with adrenal incidentaloma tied to sex? 102
Pregnancy after azathioprine therapy for ulcerative colitis in a woman with autoimmune premature ovarian failure and Addison's disease: HLA haplotype characterization. 101
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches 101
Persistent severe visual field impairment is associated with obesity and tumour invasiveness, but not with pituitary dysfunction, in patients with craniopharyngioma 99
X-linked acrogigantism: a new condition of growth hormone excess. 98
Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report 98
New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study 97
Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone-secreting adrenal phaeochromocytoma: review of the literature and report of a case 92
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies 92
Epidemiological analysis to identify predictors of X-linked hypophosphatemia (XLH) diagnosis in an Italian pediatric population: the EPIX project 91
GPR101 variants in acromegaly: results from a large series of patients. 91
The ubiquitin-specific peptidase 8 (USP8) gene is frequently mutated in adenomas causing Cushing's disease 91
What we have to know about corticosteroids use during Sars-Cov-2 infection 91
Metabolic comorbidities in Cushing's syndrome 90
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients 89
How to diagnose and manage Cushing's disease during pregnancy, when hypercortisolism is mild? 88
The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing cushing's disease 85
Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas 84
Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms 84
Endocrine disruptors, aryl hydrocarbon receptor and cortisol secretion 82
Unique clinical picture in patients with X-linked acrogigantism 82
Landscape of familial isolated and young-onset pituitary adenomas: Prospective diagnosis in AIP mutation carriers 82
Metabolic syndrome in cushing's syndrome patients 82
Approccio al paziente con tumore ipofisario aggressivo 80
What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study 80
Systemic comorbidities induce early vascular alterations in patients with active acromegaly. 78
Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor 78
The Enhanced Proteasomal Degradation of AIP Mutant Proteins Is a Mechanism for AIP Deficiency in AIP mutation-Associated Pituitary Adenomas 78
Somatic mutations in USP8 are frequent events in pituitary tumors causing Nelson's syndrome 77
L'acromegalia 77
Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications 77
Totale 13.246
Categoria #
all - tutte 45.439
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.439


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202168 0 0 0 0 0 0 0 0 0 34 11 23
2021/2022656 1 69 12 30 18 10 27 23 10 95 119 242
2022/20231.710 162 177 77 132 112 157 36 91 683 14 43 26
2023/2024453 31 76 22 42 39 102 6 46 2 28 4 55
2024/20252.616 54 36 70 168 171 78 86 484 606 204 268 391
2025/20267.554 438 462 582 500 746 1.617 933 970 989 317 0 0
Totale 14.482